Senseonics' FDA-approved CGM has a sensor that lasts six months, a first for any CGM. Other competing solutions from Medtronic and Dexcom last anywhere between three to 10 days.
The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months for adults with diabetes, according to a company press release.
Senseonics’s Eversense E3 continuous glucose monitoring system is a fully implantable third-generation sensor that connects to a removable smart transmitter and mobile app displaying glucose values, trends and
Senseonics earns FDA approval for long-lasting device for diabetes patients bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Senseonics Holdings (SENS) Announces FDA Approval of the Eversense E3 Continuous Glucose Monitoring System streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Real-time glucose data and alerts from the world's first and only long-term CGM system can now be remotely monitored by friends and family of Eversense users on Android and iOS operating system Senseonics